Ranibizumab

Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research.


Cat. No.: EX-A4356	Purity: >98%

	Chemical structure of Ranibizumab

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
50mg	Get quote	In-stock
100mg	2285	In-stock
200mg	Get quote	In-stock
500mg	Get quote	In-stock
1g	Get quote	In-stock
100mg	Get quote	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	RG-6321
CAS No.	347396-82-1
Purity	>98%
Formula	C2158H3282N562O681S12
Mol Weight	48350
Appearance	Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)[1]. Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research
Shelf Life	>2 years if stored properly
Storage	Store at 4℃, do not freeze
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. Shipping with ice bag upon request

Reference:	[1]. Mustafa Şahiner, et al. The Effects of Anti-Vascular Endothelial Growth Factor Drugs on Retinal Pigment Epithelial Cell Culture. Turk J Ophthalmol. 2018 Aug;48(4):190-195. [2]. K J Kim, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7(1):53-64. [3]. Richard Filek, et al. Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. Clin Ophthalmol. 2019 Jul 1;13:1097-1114.
CoA	CoA of Ranibizumab


		Search